WaferGen, MPLN Partner on NGS-based Clinical Test Development | GenomeWeb

NEW YORK (GenomeWeb) – WaferGen Biosystems today announced a partnership with Molecular Pathology Laboratory Network to develop next-generation sequencing-based clinical tests.

According to MPLN VP of Genomic Solutions Jamie Platt, the first product to be commercialized from the deal will be a solid tumor panel to complement the lab's Pathology Partners Program and support MPLN's expanding molecular oncology services menu.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Three researchers win the Nobel Prize for their efforts to develop treatments for parasitic diseases.

In PLOS this week: effect of variants linked to body shape differs by age and sex, transcriptome differences in bats with and without white-nose syndrome, and more.

A researcher argues that big prizes like the Nobel or Lasker awards send the wrong message about research.

Maria Freire, the president of the Foundation for the National Institutes of Health, discusses recent genomics-fueled advances with The Open Mind's Alexander Heffner.

Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.